放疗联合PD-1抑制:脑定向放疗后结局良好
该多中心回顾性研究纳入137例接受放疗及抗PD-1治疗的转移性NSCLC、黑色素瘤和RCC患者,发现PD-1治疗开始后接受放疗者中部分可继续PD-1治疗并延长生存,脑转移放疗后中位生存达634天。
要点
- PD-1治疗开始后放疗者中25例继续PD-1治疗中位179天,额外生存中位238天。
- 脑转移首次放疗后中位生存634天,优于历史对照。
- 黑色素瘤患者在PD-1治疗开始后接受脑定向放疗相对较少。
核心结论
- 姑息放疗不排除PD-1抑制剂治疗患者获得良好结局。
- PD-1抑制开始后接受放疗的患者可继续PD-1治疗并显示延长生存。
- 脑转移放疗患者结局优于历史对照。
研究设计与样本
- 多中心回顾性研究,纳入四中心连续接受放疗及抗PD-1治疗的转移性NSCLC、黑色素瘤和RCC患者。
主要发现
- 共纳入137例接受放疗和PD-1抑制的患者。
- 从首次PD-1治疗起中位生存:NSCLC 192天,黑色素瘤394天,RCC 121天。
- PD-1阻断开始后接受放疗的59例中,25例继续PD-1抑制中位179天,额外生存中位238天。
- 脑转移首次放疗后中位生存634天。
临床怎么用
- 对接受PD-1抑制剂的转移性NSCLC、黑色素瘤和RCC患者,可考虑整合姑息放疗。
- PD-1治疗开始后需放疗者,放疗后仍可继续PD-1治疗。
- 脑转移患者接受放疗可获得较好生存结局。
局限性
- 回顾性研究设计。
- 样本量有限(137例)。
- 结局数据来自四中心连续患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Patients with metastatic melanoma, renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) are increasingly treated with immune checkpoint blockade targeting the programed death (PD)-1 receptor, often with palliative radiation therapy. Outcome data are limited in this population. MATERIAL AND METHODS: We retrospectively reviewed consecutive patients with metastatic NSCLC, melanoma, and RCC who received radiation and anti-PD-1 therapy at four centers. RESULTS: We identified 137 patients who received radiation and PD-1 inhibition. Median survival from first PD-1 therapy was 192, 394, and 121days for NSCLC, melanoma, and RCC patients. Among 59 patients who received radiation following the start of PD-1 blockade, 25 continued to receive PD-1 inhibition for a median of 179days and survived for a median of 238 additional days. Median survival following first course of radiation for brain metastases was 634days. Melanoma patients received brain directed radiation relatively less frequently following the start of PD-1 inhibitor treatment. CONCLUSIONS: Incorporation of palliative radiation does not preclude favorable outcomes in patients treated with PD-1 inhibitors; patients irradiated after the start of PD-1 inhibition can remain on therapy and demonstrate prolonged survival. Of note, patients irradiated for brain metastases demonstrate favorable outcomes compared with historical controls.
引用
- Pike LRG, Bang A, Ott P, et al. Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother Oncol. 2017. PMID: 28662869. doi:10.1016/j.radonc.2017.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。